HomeNewsTrendsEntertainmentWhat other studios can learn from Yoodlee Films in the time of COVID-19
Trending Topics

What other studios can learn from Yoodlee Films in the time of COVID-19

With its focus on great content and tight budget control, this young studio has many lessons for the film industry at a time when it is grappling with the challenges posed by the coronavirus outbreak

July 24, 2020 / 15:28 IST
Story continues below Advertisement

In 2017, Vikram Mehra, MD of Saregama India, India’s oldest music label, was toying with the idea of setting up a film studio that focussed on story-led cinema instead of star-led films. Everyone around him agreed there was a market for such films, but warned that he would have to keep costs under control.

“Every big producer says a movie doesn’t flop, budgets flop,” said Mehra, in a chat with Moneycontrol. With this caveat serving as a guiding principle, he went on to set up Yoodlee Films as the film division of Saregama India, an RP Sanjiv Goenka Group company. Mehra focussed on marrying great content with smart budgets, and that model holds many lessons for other film production houses today, when they are grappling with the Covid outbreak.

Story continues below Advertisement

The studio’s name was derived from yodelling, a form of singing characterised by rapid changes in pitch, and popularised in India by Kishore Kumar. “It symbolises the history of Saregama as a company, while also serving as the wolf howl of younger audiences, our films’ targets,” said Mehra.

Yoodlee released its first film, Ajji, in November 2017. The modern-day adaptation of the children’s tale Little Red Riding Hood, directed by Devashish Makhija, won critical acclaim. In all, Yoodlee has made 13 films in the last two-and-a-half years for both theatrical as well as direct-to-digital release.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show